Eloxx Pharmaceuticals raises ~$2M in registered direct offering and private placement

Eloxx Pharmaceuticals, Inc.

Sold 305,590 shares + 75,000 pre-funded warrants at ~$5.255/unit, and 380,590 private warrants at $5.13 exercise.
Gross proceeds approximately $2.0M; H.C. Wainwright placement agent with 7.5% fee and 22,835 warrant shares.
Private and placement warrants issued unregistered under Section 4(a)(2) exemption.
Pre-funded warrant exercise price $0.001; private warrant term 5.5 years; both have beneficial ownership caps.
Proceeds intended for general corporate purposes.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Eloxx Pharmaceuticals, Inc. entered into Purchase Agreement with a certain institutional investor (effective 2023-09-18).

Action: entry
Agreement: equity purchase
Counterparty: a certain institutional investor
Effective: 2023-09-18

Exact text from the filing

On September 18, 2023, Eloxx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor (the “Purchaser”).

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

Eloxx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-102293

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.